Efficacy News and Research

RSS

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

DURECT Corporation announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR, DURECT's proprietary investigational transdermal bupivacaine pain patch.

12 Apr 2011

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter International Inc. announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients.

From Baxter International Inc. 12 Apr 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

VIVUS, Inc. today announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.

11 Apr 2011

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

The Canadian Association of PNH Patients welcomes the upcoming publication of a study that resoundingly proves the efficacy of Soliris, the first and only life-saving treatment for the ultra-rare blood disease known as Paroxysmal Nocturnal Haemoglobinuria.

11 Apr 2011

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

Diamyd Medical´s Phase I clinical trial results evaluating the safety and efficacy of the candidate drug NP2 Enkephalin to treat intractable cancer pain has been published in the medical journal Annals of Neurology.

11 Apr 2011

New point-of-care trial can reduce cost and length of studies

Doctors at the Veterans Affairs Boston Healthcare System are testing a new kind of clinical trial that's not only less costly but guides doctors to switch to the best treatment even before the trial is completed.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Louisville Chief of Cardiovascular Medicine earns APS' Walter B. Cannon Award

Heart failure affects roughly six million Americans, yet treatment consists of either a heart transplant or the insertion of mechanical devices that assist the heart. This is unacceptable to Roberto Bolli, MD, Chief of the Division of Cardiovascular Medicine at the University of Louisville in Louisville, Ky., which is why he is on a mission to make cardiac stem cell treatment an option for all who must cope with the limitations of a failing heart.

11 Apr 2011

Elekta to highlight Leksell Gamma Knife Perfexion radiosurgery solution at AANS 2011

At the 2011 American Association of Neurological Surgeons (AANS) Annual Meeting, April 9-13 at the Colorado Convention Center, Elekta (booth #1717) will highlight characteristics of Leksell Gamma Knife® Perfexion™ that separate the system from other radiosurgery solutions.

From Elekta 8 Apr 2011

Current 'metrics' don't paint clear picture of health care quality

With a push to make hospitals and doctors more accountable for health care quality, more attention must be paid to the accuracy and reliability of measures used to evaluate caregivers, says a prominent Johns Hopkins patient safety expert.

8 Apr 2011

Researchers test plants used in traditional African medicine against malaria

The malaria parasite has gradually developed resistance to the most commonly used medicines. To make matters worse, several mosquito species that host and transmit the parasite have become resistant to insecticides, making it difficult to eliminate them from populated areas.

8 Apr 2011

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye, an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema.

8 Apr 2011

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

Targacept, Inc. today announced the presentation of data from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia at the International Congress on Schizophrenia Research in Colorado Springs, Colorado.

8 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Johns Hopkins patient safety expert: Unreliable "outcomes" measures hamper efforts to assure better, safer care

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.

7 Apr 2011

Efficacy News and Research

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

The Lancet publishes VIVUS 56-week QNEXA study results in obesity

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

Annals of Neurology publishes Diamyd Medical´s NP2 Enkephalin Phase I results in cancer pain

New point-of-care trial can reduce cost and length of studies

Gilenya can reduce risk of disability progression in patients with RRMS

Louisville Chief of Cardiovascular Medicine earns APS' Walter B. Cannon Award

Elekta to highlight Leksell Gamma Knife Perfexion radiosurgery solution at AANS 2011

Current 'metrics' don't paint clear picture of health care quality

Researchers test plants used in traditional African medicine against malaria

Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

AJG publishes new review on Inflammatory Bowel Disease management

Johns Hopkins patient safety expert: Unreliable "outcomes" measures hamper efforts to assure better, safer care

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News